Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UJA5
UPID:
TRM6_HUMAN
Alternative names:
mRNA methyladenosine-N(1)-methyltransferase non-catalytic subunit TRM6; tRNA(m1A58)-methyltransferase subunit TRM6
Alternative UPACC:
Q9UJA5; B4DUV6; Q76P92; Q9BQV5; Q9ULR7; Q9Y2Z8
Background:
The tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6 plays a pivotal role in the post-transcriptional modification of RNA, specifically in the methylation of adenosine residues. This process is crucial for the proper functioning of tRNA and certain mRNAs, impacting protein synthesis and cellular function. TRM6, in collaboration with TRMT61A, facilitates the formation of N(1)-methyladenine at position 58 in initiator methionyl-tRNA, a modification essential for mRNA stability and translation efficiency.
Therapeutic significance:
Understanding the role of tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6 could open doors to potential therapeutic strategies. Its involvement in RNA methylation presents a unique target for modulating gene expression and protein synthesis, offering avenues for the development of novel treatments in diseases where these processes are dysregulated.